Skip to main content

Table 2 Circulating miRNAs as potential prognostic predictors of ovarian cancer

From: Clinical relevance of circulating cell-free microRNAs in ovarian cancer

Reference

miRNAs associated with poor prognosis

Endpoint

Source

Patients (n)

Histology (n)

FIGO stage (n)

 

Increased miRNAs

Decreased miRNAs

   

Serous

Others

I-II

III-IV

[69], 2013

 

let-7f

PFS

Plasma

360

179

181

133

227

[71], 2013

miR-21

 

OS

Serum

94

68

26

32

62

[72], 2013

miR-221

 

OS

Serum

96

70

26

32

64

[74], 2014

 

miR-1290

OS

Plasma

26

26

0

6

36

[38], 2014

miR-21,miR-23b, miR-29a (PFS), miR-21(OS)

 

PFS/OS

Effusion (exosome)

86

76

10

0

86

[75], 2015

miR-429

 

OS

Serum

180

180

 

32

147

[76], 2015

miR-141

miR-200c

OS

Serum

74

16

58

54

20

[77], 2015

 

miR-145

OS

Serum

82

18

64

31

53

[80], 2015

miR-200b

 

PFS

Plasma

33

33

 

Unknown

 
  1. FIGO: International Federation of Obstetrics and Gynecology, PFS: progression free survival, OS: overall survival
Back to article page

Molecular Cancer

ISSN: 1476-4598